Rockefeller University Press

Table II.

Splenocytes from 7 and 8 d after LCMV Inoculation Were Stimulated In Vitro with LCMV-specific Peptides and Cytokine Production Was Assessed by Flow Cytometry

		IFN-γ							IL-2
		Percentage of splenic  CD8⁺ T cells^{^a}^,^{^b}			Percentage of splenic  CD4⁺ T cells^{^a}^,^{^b}			Percentage of splenic  CD8⁺ T cells^{^a}^,^{^b}		Percentage of splenic  CD4⁺ T cells^{^a}^,^{^b}
Group		GP 33–41	NP 396–404	GP 61–80	NP 309–328	GP 33–41	NP 396–404	GP 61–80	NP 309–328
JNK1^−/−	D7	22 ± 1	15 ± 1	5.0 ± 0.3	1.1 ± 0.3	1.8 ± 0.3	0.6 ± 0.1	2.6 ± 1	0.3 ± 0.05
	D8	36 ± 1	18 ± 1	4.9 ± 0.5	1.7 ± 0.2
JNK2^−/−	D7	26 ± 2	18 ± 2	7.4 ± 1.3	1.5 ± 0.2	1.2 ± 0.1	0.6 ± 0.1	4.5 ± 0.5	0.3 ± 0.05
	D8	53 ± 2^{^c}	29 ± 3^{^c}	11.1 ± 1.7^{^d}	1.8 ± 0.4
JNK^+/+	D7	23 ± 1	14 ± 1	6.1 ± 1.0	1.4 ± 0.5	1.4 ± 0.1	0.3 ± 0.03	3.6 ± 0.5	1.0 ± 0.4
	D8	30 ± 2	16 ± 1	6.3 ± 0.9	2.3 ± 0.3

		IFN-γ							IL-2
		Percentage of splenic  CD8⁺ T cells^{^a}^,^{^b}			Percentage of splenic  CD4⁺ T cells^{^a}^,^{^b}			Percentage of splenic  CD8⁺ T cells^{^a}^,^{^b}		Percentage of splenic  CD4⁺ T cells^{^a}^,^{^b}
Group		GP 33–41	NP 396–404	GP 61–80	NP 309–328	GP 33–41	NP 396–404	GP 61–80	NP 309–328
JNK1^−/−	D7	22 ± 1	15 ± 1	5.0 ± 0.3	1.1 ± 0.3	1.8 ± 0.3	0.6 ± 0.1	2.6 ± 1	0.3 ± 0.05
	D8	36 ± 1	18 ± 1	4.9 ± 0.5	1.7 ± 0.2
JNK2^−/−	D7	26 ± 2	18 ± 2	7.4 ± 1.3	1.5 ± 0.2	1.2 ± 0.1	0.6 ± 0.1	4.5 ± 0.5	0.3 ± 0.05
	D8	53 ± 2^{^c}	29 ± 3^{^c}	11.1 ± 1.7^{^d}	1.8 ± 0.4
JNK^+/+	D7	23 ± 1	14 ± 1	6.1 ± 1.0	1.4 ± 0.5	1.4 ± 0.1	0.3 ± 0.03	3.6 ± 0.5	1.0 ± 0.4
	D8	30 ± 2	16 ± 1	6.3 ± 0.9	2.3 ± 0.3

Average of four mice per group.

Percentage of CD8⁺ or CD4⁺ positive for cytokine as measured by flow cytometry ± standard error.

P < 0.05 compared to JNK^+/+.

P = 0.05.

D7, day 7; D8, day 8.

View Large

This Feature Is Available To Subscribers Only